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ABSTRACT

ANAAM F. MOHAMMED
Assessment of Rotavirus Vaccine Type and Number of Doses on Severity of Disease
(Under the direction of Dr. Lisa Casanova, Faculty Member)

Background: Rotavirus disease is the leading global cause of severe diarrhea in children under 5
years. We examined the association between different rotavirus vaccines doses and severity of
diarrhea.
Methods: A secondary analysis of surveillance of children with acute gastroenteritis (AGE)
symptoms during two seasons (January-June) in 2010 and 2011 from three pediatric hospitals in
Atlanta, Georgia was conducted. Enrolled children were tested for rotavirus, using EIA
(Rotaclone) and vaccination records were collected from the state immunization registry and
healthcare providers. Cases were defined as any enrolled child who tested positive for rotavirus.
Each enrolled child was assigned a Vesikari score to assess AGE severity.
Results: 63.9% of participants had severe AGE. Cases were more likely to have severe AGE
than controls (OR 3.8, 95% CI: 2.2-6.5). Receiving a mixed vaccine regimen had similar
protection against severe disease to receiving only RotaTeq® or Rotarix® (Mixed: OR 0.1, 95%
CI: 0.02-0.5; RotaTeq®: OR 0.1, 95% CI: 0.02-0.5; Rotarix®: OR 0.1; 95% CI 0.01-0.3). When
controlling for vaccine type and demographic covariates, three doses of vaccine offered
significant protection against severe disease (OR 0.3, 95% CI: 0.2-0.6).
Conclusions: Receiving a mixed regimen of rotavirus vaccine is effective in preventing severe
AGE. Mixed rotavirus vaccine regimens were equally efficacious to receiving a single type of
vaccine in preventing severe disease. Three doses of vaccine, regardless of type, were effective
in preventing severe disease but one or two doses were not.
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CHAPTER I:
INTRODUCTION

1.1 Background
Rotavirus remains the leading cause of severe diarrhea in children under the age of five
worldwide. In 2008, rotavirus was responsible for 453,000 deaths among children younger than
five.20 Rotavirus is the most common organism which causes gastroenteritis in children. Deaths
due to rotavirus overwhelmingly occur in developing countries, with approximately 85% of all
rotavirus deaths occur in Africa and Asia. The World Health Organization estimates that
rotavirus diarrhea results in approximately half a million deaths and approximately 2.4 million
hospitalizations in developing countries each year.2
There are currently two widely used rotavirus vaccines: Rotarix® (GlaxoSmithKline
Biologicals), a human, live attenuated 2-dose vaccine and RotaTeq® (Merck), a live, oral
pentavalent 3-dosevaccine.2 Rotavirus vaccines have been included in the regular immunization
schedule for children in the US since 2006. Efficacy of RotaTeq® and Rotarix® ranges from
39% to 77% in developing countries, such as those in Africa and Asia.3 Several studies
conducted in the United States have reported considerable reduction in illness caused by
rotavirus after the introduction of rotavirus vaccines. Similarly, a greater number of rotavirus
vaccine doses have been associated with reduction in disease complications.8 In developed
countries, rotavirus vaccines have demonstrated high efficacy against severe rotavirus disease
(pooled efficacy =85%).9 A recent study of the effectiveness of both rotavirus vaccines in Spain
revealed no significant differences between RotaTeq® and Rotarix®.10 The efficacy of mixed
doses has not been previously assessed.

1.2 Purpose of Study
To determine the effect of receiving Rotarix®, RotaTeq®, or a mixed dose of the
vaccines on the severity of rotavirus disease, this secondary analysis of a case-control study of
participants from Children’s Healthcare of Atlanta hospitals was undertaken. The purpose of this
study was to examine the association between the type and number of doses of rotavirus vaccine
and the severity of disease in children under three.
1.3 Research Questions
1. Does the type of rotavirus vaccine children receive (RotaTeq® vs. Rotarix® vs. mixed)
affect the severity of their disease as measured by the Vesikari scale?
2. Does the number of doses of rotavirus vaccine children receive affect the severity of their
disease as measured by the Vesikari scale?

CHAPTER II:
LITERATURE REVIEW

2.1 Burden of Rotavirus Disease
Rotavirus is the leading cause of severe diarrhea in children under the age of five
worldwide. By the age of five, nearly every child in the world has been infected with rotavirus at
least once.1 Deaths due to rotavirus occur disproportionately in developing countries, with
approximately 85% of all rotavirus deaths occurring in Africa and Asia.2 Prior to the introduction
of the rotavirus vaccines, over 40% of pediatric hospital admissions for diarrhea worldwide were
caused by rotavirus infections.10
Similarly, United States hospital discharge database, the Healthcare Cost and Utilization
Project (HCUP) data was used to extrapolate that rotavirus was the cause of ~60,000
hospitalizations and 37 deaths in the US annually.16 Before the introduction of rotavirus vaccines
in the US, 410,000 doctor’s visits, 70,000 hospitalizations, and 272,000 Emergency Department
(ED) visits were attributed to rotavirus annually. This burden represented a societal cost of close
to $1 billion.23
In 2007, rotavirus diarrhea was associated with an estimated annual healthcare cost of
$319 million and a total annual cost to society of $893 million.17 The rotavirus gastroenteritisassociated hospitalization burden is substantial, both in terms of the number of hospital visits and
the cost.18
2.2 Disparities in Rotavirus Disease in the United States
Although national introduction of both RotaTeq® and Rotarix® has caused an overall
decline in rotavirus gastroenteritis hospitalizations in children of all races, the same disparities in

rotavirus disease observed in pre-vaccine years persist in the US. Particularly, race and insurance
status account for some of the disparities.16-18 For example, the Medicaid population had a
disproportionate number of hospitalizations from rotavirus gastroenteritis than non-Medicaid
populations.18
Adjusting for age, Black children were found to have a lower visit rate for diarrhea
associated illness than White children in outpatient setting but a higher visit rate for diarrheaassociated illness in the ED setting. Conversely, Whites had a significantly greater (40%) rate of
healthcare utilization for diarrhea-associated illness outpatient clinics than Blacks, but Blacks
utilized the ED for diarrhea-associated illness at nearly double the rate of Whites. These data
suggest that race may influence site of care for diarrhea-associated illness in children.17
Similarly, data from HCUP found that Black infants had a significantly higher risk of being
hospitalized and dying from rotavirus early in life, when compared to Whites.16
2.3 History of Rotavirus Vaccines
The first rotavirus vaccine was introduced in 1998. RotaShield® (Wyeth) was a
tetravalent vaccine that contained the G1-G4 rotavirus strains. After clinical trials that proved it
to be 80-100% effective in preventing severe diarrhea, RotaShield® was licensed for use in the
US. However, it was later discovered to have possibly contributed to an increased risk for
intussusception in one in every 12,000 vaccinated infants, and was therefore, removed from the
market in 1999.20
In 2006, two new rotavirus vaccines were introduced: RotaTeq® and Rotarix®.2,10 In the
US, the rotavirus vaccines were first recommended for all children in February 2006. Three years
later, the World Health Organization Strategic Advisory Group of Experts recommended the
rotavirus vaccine for all children. As of 2011, Rotarix® had been introduced into 27 national

vaccine programs, and RotaTeq® had been introduced into 7national vaccine programs. Some
countries, such as the US and Australia offer both vaccines, whereas others have switched from
RotaTeq® to Rotarix® or vice versa or have still not introduced the vaccines.7,10 It is estimated
that introduction of rotavirus vaccines in low-income countries would prevent 45% of deaths and
approximately 58% of associated medical visits and costs due to rotavirus.24
Tracking intussusception rates before (2000-2005) and after (2007-2009) the introduction
of RotaTeq® and Rotarix®, Yen and colleagues found a small increase in intussusception rates
have been seen among infants aged 8-11 weeks with the first dose of the current rotavirus
vaccines. Despite this, no population level changes in rates of intussusception hospitalizations
have been noted.15
In March 2010, porcine circovirus-1 (PCV-1) was identified in the Rotarix® vaccine.
PCV-1 infects pigs but is not known to cause infections in humans. Still, the US Food and Drug
Administration suspended use of Rotarix®. Further testing of both rotavirus vaccines revealed
that RotaTeq® contained small amounts of PCV-1 and PCV-2, another porcine circovirus strain.
The Rotarix® ban was removed by the FDA later in 2010 because the PCV strains pose only a
theoretical risk to humans, as there has been no documented human infection by PCV strains.25
2.4 Differences between Rotarix® and RotaTeq®
RotaTeq ® (RV1)

Rotarix ® (RV5)

Manufacturer

Merck

GlaxoSmith Kline Biologicals

Conception

Live, oral pentavalent

Human, live attenuated

Antigenic Composition

G1, G2, G3, G4, P1A ressortant
strains from bovine strain WC3
(type G6P7[5])

G1P1A[8] from the human strain
89-12

Number of Doses

3

2

Schedule

2, 4, and 6 months
(first dose should be given within

2 and 4 months
(first dose should be given within

6-15 weeks of age and the last
dose by 8 months of age, with at
least 4 weeks in between doses)
Adapted from Lopman, et al., 2012.

6-15 weeks of age and the last
dose by 8 months of age, with at
least 4 weeks in between doses)

2.5 Rotavirus Vaccine Efficacy
Introduction of the rotavirus vaccines has been associated with reductions in
gastroenteritis mortality.7 Substantial reductions in rotavirus hospitalizations in middle and highincome countries have been observed as well. In high-income countries, including the US,
Australia, Austria, Spain, and Israel, vaccine effectiveness was >85%, similar to that of clinical
trials.10, 26-29 In upper middle-income Latin American countries, such as Mexico and Brazil,
vaccine effectiveness varied from 79 to 94%.30-32 Effectiveness in El Salvador, a low middleincome country, was 76%, not much different than the effectiveness in higher middle-income
countries.33
In developing countries in Africa and Asia, the efficacy of RotaTeq® and Rotarix®
ranges from 39-77%. Though the efficacy of rotavirus vaccines is lower in developing countries
than developed ones, the indirect vaccine benefits, such as herd immunity, are especially
important in developing countries. These indirect benefits help to reduce transmission of
rotavirus within the community. After the introduction of the rotavirus vaccines in low-middle
and middle income Latin American countries, deaths and hospitalizations due to rotavirus
decreased.3 Specifically, clinical trials in the high-mortality, low–income countries of South
Africa and Malawi found a significant decrease in severe diarrheal episodes due to rotavirus after
the introduction of the vaccine. 2 This suggests that similar reductions will take place in other
high-mortality, low-income countries.
Wang and colleagues assessed the effectiveness of RotaTeq® following partial
completion of the 3-dose regimen. One dose of RotaTeq® was associated with being 88%

effective against preventing rotavirus gastroenteritis hospitalizations and ED visits and 44%
effective against preventing all gastroenteritis hospitalizations and ED visits. Two doses of the
vaccine were associated with 94% effectiveness in preventing rotavirus gastroenteritis
hospitalizations and ED visits and 40% in preventing all gastroenteritis hospitalizations and ED
visits. This illustrates that RotaTeq ® is effective against rotavirus even before a full vaccine
regimen in complete.4 Likewise, another study found that RotaTeq® begins to protect children
against hospitalizations and ED visits for rotavirus gastroenteritis as early as 14 days after the
first dose and between doses as well.5
Few rotavirus vaccine efficacy studies have addressed both RotaTeq® and Rotarix® or a
mixed vaccine regimen.
2.6 Vesikari Scale
The Vesikari scale was developed in 1990 to assess diarrheal disease severity. It
measures the duration of diarrhea, the maximum number of stools in a 24 hour period, the
duration of vomiting, the maximum number of vomiting episodes in a day, temperature,
dehydration, and treatment. The Vesikari scale is a widely accepted 20-point scale, in which a
score of 1-10 indicates non-severe disease, and a score of 11 or above indicates severe disease.12
It has been used to assess disease severity in vaccine efficacy studies of both RotaTeq® and
Rotarix® in the US, Latin American, African, Middle Eastern, Asian, and European
countries.13,21-22

CHAPTER III:
METHODOLOGY

3.1 Study Design
The methodology of this case-control study has been described elsewhere.11 Briefly, active
acute gastroenteritis (AGE) surveillance was conducted from January through June of 2010 and
for the same period during 2011 in the Emergency Departments (ED) and inpatient floors at the
three Children’s Healthcare of Atlanta (CHOA) hospitals. Parents of children who presented
with a complaint of diarrhea were approached for enrollment. Patients were eligible for
enrollment if they were: (1) diagnosed with acute gastroenteritis (AGE) defined as ≥ 3 looser
than normal stools within a 24-hour period and diarrhea < 10 days at time of enrollment; (2)
managed as an ED patient, short-stay patient, or inpatient; (3) had no immunocompromising
condition (e.g. malignancy, HIV infection); (4) had a stool sample collected from the patient
within 14 days of presentation of illness with results available from a rotavirus antigen
immunoassay; (5) eligible to have received at least 1 RV dose >14 days before presentation
according to birth date (6) born on or after March 1, 2009 and age at evaluation >56days; and (7)
lived in the usual catchment area of the hospital.
Rotavirus testing on stool specimens was conducted at the Centers for Disease Control
and Prevention (CDC) using commercial enzyme immunoassay (EIA) kit (Rotaclone) to
determine whether patients were rotavirus positive (cases) or rotavirus negative (controls).
This study was approved by institutional review boards of Morehouse School of
Medicine, CDC and CHOA.

3.2 Study Measures
Severity of disease was determined using the Vesikari scale. The Vesikari scale measures
duration of diarrhea, maximum number of diarrheal episodes in a 24 hour period, duration of
vomiting, maximum number of vomiting episodes in a 24 hour period, temperature, dehydration,
and treatment. The Vesikari scale is a 20-point scale in which a score of >11 is considered
severe. A score of 1-10 on the Vesikari scale is considered not severe. Patients were, therefore,
classified as having severe or non-severe disease.12-14 Severe and non-severe patients were
further categorized based on whether they received Rotarix®, RotaTeq®, or a mixed vaccine
regimen and how many doses of rotavirus vaccine they received. Vaccine information was
obtained from the state immunization registry and provider records.
3.3 Study Definitions
Vaccine Type
Participants were grouped into vaccine type cohorts based on their vaccine history at the
time of illness, which was obtained from provider records and the state immunization registry.
Participants categorized as RotaTeq® or Rotarix® only received that respective vaccine,
regardless of the number of doses received. Receiving a mixed vaccine dose was defined as
receiving at least one dose of RotaTeq® and at least one dose of Rotarix®.
Race
Race was reported by the study participants’ guardian. The other race category included
Asian, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or unknown.
Insurance Status
Public insurance included Medicaid programs. Private insurance included PPO, HMO,
and POS programs.

3.4 Statistical Analyses
The rotavirus positive and negative cohorts were established based on laboratory testing of
stool samples. Odds ratios and a corresponding 95% CI for the relationship between disease
status, vaccine type, number of doses of vaccine received, race, and insurance status and disease
severity were calculated for each vaccine group. Similar analyses were conducted based on the
number of doses of vaccine received. Univariate regression analysis of disease severity by
disease status, vaccine type, number of vaccine doses, race, and insurance status were conducted.
Multivariate regression analysis between disease severity and vaccine type while controlling for
number of vaccine doses and demographic covariates were conducted as well.
All analyses were conducted using a statistical software package (SPSS 19.0 version for
Windows; SPSS Inc., Chicago, IL, USA).

CHAPTER IV:
RESULTS

4.1 Descriptive Statistics
In two separate rotavirus seasons (January-June 2010 and 2011), 660 children who
presented with AGE symptoms to one of the three CHOA hospitals' ED or inpatient departments
were approached for enrollment into the study. One hundred and eleven guardians of approached
patients declined participation. Reasons for refusal included not wanting to participate in
research and not wanting to collect stool. Of the 549 children who consented to be in the study,
stool samples were collected from 430 of them, and the remaining 119 patients were lost to
follow up. Three of the subjects had to be withdrawn from the study. One subject was less than
55 days old. A stool sample was collected more than 14 days after enrollment for another
subject. The third subject was a duplicate enrollment. The remaining 427 stool samples were
tested for rotavirus, and 119 were found to be rotavirus positive, whereas the other 308 were
negative (Figure 1).
More than half of all study participants, 273 (63.9%) had severe disease. In each vaccine
type category, majority of participants had severe disease. Ninety-five (77.2%) children who did
not receive, 48 (64.0%) children who received RotaTeq®, 73 (56.5%) children who received
Rotarix®, 33 (55.9%) children who received mixed vaccine regimens, and 24 (60.0%) children
who received at least one dose of an unknown vaccine type all developed severe disease.
Similarly, 29 (65.9%) children who received only 1 vaccine dose, 103 (65.9%) children who
received 2 doses, and 46 (52.3%) children who received 3 doses of rotavirus vaccine all
developed severe disease (Table 2).

119 (27.9%) participants were rotavirus positive and 308 (72.1%) were rotavirus
negative. The largest vaccine group was Rotarix®, 130 (30.4%), followed by no vaccine, 123
(28.8%), RotaTeq®, 75 (17.6%), and mixed dosing, 59 (13.8%). 40 (9.4%) participants received
at least one unknown type of rotavirus vaccine. Study participants were most likely to receive 2
doses of vaccine 172 (40.3%) or no vaccine 123 (28.8%). Majority of participants were Black,
265 (62.1%) and had public insurance (multiple programs), 330 (72.2%) (Table 1).
There was a significant difference in the likelihood of racial groups to be vaccinated
(receive at least one dose of a rotavirus vaccine) (p-value: 0.001). Specifically, Hispanic children
were more likely to be vaccinated than White children (OR 2.7, 95% CI: 1.1-6.7). There was no
significant difference in the likelihood of Black children to be vaccinated when compared to
White children (OR 0.7, 95% CI: 0.4-1.3). No significant differences were observed in the
likelihood of children with public and private insurance to be vaccinated (p-value: 0.251).
4.2 Univariate Analyses
Rotavirus positive children were more likely to have severe disease than rotavirus
negative children (OR 3.8, 95% CI: 2.2-6.5). Receiving a mixed vaccine regimen had similar
protection against severe disease to receiving only RotaTeq® or Rotarix® (Mixed: OR 0.4, 95%
CI: 0.2-0.7; RotaTeq®: OR 0.5, 95% CI: 0.3-0.90; Rotarix®: OR 0.4, 95% CI: 0.2-0.7).
Receiving one or two doses of vaccine, regardless of type, was protective against severe disease,
when compared to children who did not receive vaccine (2 doses: OR 0.6, 95% CI: 0.3-0.9; 3
doses: OR 0.4, 95% CI: 0.2-0.7). Black and Hispanic children were less likely to develop severe
disease than White children (Black: OR 0.4, 95% CI 0.2-0.9; Hispanic: OR 0.3, 95% CI: 0.10.7). Children with private insurance were also more likely to develop severe disease than those
without insurance (OR 3.1, 95% CI 1.2-8.3) (Table 3).

4.3 Multivariate Analyses
When controlling for number of doses and demographic covariates, receiving only
RotaTeq® (n=75), only Rotarix® (n=130), or a combination of the two vaccines (n=59) all
provided significant protection against severe disease when compared to children who did not
receive vaccine (Mixed: OR 0.1, 95% CI: 0.02-0.5; RotaTeq®: OR 0.1, 95% CI: 0.02-0.5;
Rotarix®: OR 0.1; 95% CI 0.01-0.3). When controlling for vaccine type and other demographic
covariates, only three doses of vaccine offered significant protection against severe disease (OR
0.3, 95% CI: 0.2-0.6). In the multivariate model, Black and Hispanic children persisted in being
less likely to develop severe disease than White children (Black: OR 0.4, 95% CI 0.2-0.8;
Hispanic: OR 0.3, 95% CI 0.1-0.7). Children with private insurance were 4.0 times more likely
to develop severe disease than those with no insurance (95% CI 1.2-12.9) (Table 4).

CHAPTER V:
DISCUSSION AND CONCLUSION

5.1 Discussion
The results of this study of children under three seen in an urban hospital system for
diarrhea suggest children who receive a mix of both RotaTeq® and Rotarix® are adequately
protected against severe disease, compared to children who do not receive vaccines. That is,
children who receive mixed rotavirus vaccine regimens fare similarly to those who only receive
RotaTeq® or Rotarix® in terms of protection against severe disease.
Our analysis also revealed that children with private insurance were more likely to
develop severe disease than children with no insurance. These findings contradict previous
studies which found that the Medicaid population had a disproportionate number of
hospitalizations from rotavirus gastroenteritis than other populations.17-18 Our contradictory
findings may be attributed to children with private insurance already seeking medical attention
elsewhere before coming to the ED, causing them to be enrolled in the study when their disease
had progressed further.
Despite well established racial and insurance-related disparities in rotavirus vaccination
and disease, the disparities found in our studies are not consistent with those found in previous
literature.15-18 We found that Black and Hispanic children were actually less likely to develop
severe disease than White children. Yen and colleagues also found that White children were
more likely to develop rotavirus gastroenteritis prior to the introduction of the rotavirus vaccines
but had largely diminished in 2008.15 Whereas Yen and colleagues' study analyzed national data,
the data set used for this study only evaluated children in the metro-Atlanta area. The national

demographic profile differs from that of the metro-Atlanta area, which could account for
different results. It is possible that although racial differences in rotavirus vaccination and
disease have been largely diminished nationally, they may persist in localized areas.
A previous study of a five year period showed that several children may be excluded
from receiving the rotavirus vaccine because they miss the age windows to receive doses.20 Our
findings suggest that availability of a specific rotavirus vaccine should not be a factor in
children’s failure to receive the rotavirus vaccine. Pediatricians should work to ensure that their
patients receive a rotavirus vaccine on the proper schedule. Specifically, a child should receive a
rotavirus vaccine on the proper schedule, even if the vaccine available at the time is not the same
brand as the one they received previously.
5.2 Limitations of the Study
This study had several limitations. Disease severity was determined using the Vesikari
scale. The Vesikari scale is dichotomous and categorizes diarrheal disease as severe or nonsevere, which does not give a full understanding of the range of disease severity among study
participants. Other scales of diarrheal disease severity categorize disease into more than two
categories. These scales also consider factors not included in the Vesikari scale, such as
behavioral signs and symptoms, to determine disease severity.19
5.3 Recommendations
In the future, it may be helpful to assess disease severity using a different scale. The sample size
used for our analysis was relatively small. More studies should be conducted to further evaluate
the efficacy of mixed rotavirus vaccine regimens.

5.4 Conclusion
Three doses of rotavirus vaccine, regardless of vaccine type, are protective against severe
disease, but one or two doses are not. Receiving a mixed regimen of vaccine is also effective in
preventing severe disease. As such, pediatricians should give patients the rotavirus vaccine on
schedule, regardless of the type of vaccine. They should also continue to stress the importance of
receiving all doses of the rotavirus vaccine. More studies should be done to evaluate the impact
and effectiveness of mixed rotavirus vaccine regimens.

Figure 1. Diagram of all patients approached and enrolled in study.
660
Approached for enrollment

111
Declined participation
549
Enrolled
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Stool samples collected

3
Withdrawn

119
Rotavirus Positive

308
Rotavirus Negative

From the 430 patients who stool samples were collected from, 3 were withdrawn from the
dataset. (One patient was younger than 55 days, one stool sample was collected more than 14
days after enrollment, and one patient had previously been enrolled in the study). Majority of the
patients who declined participation did so because they did not want to participate in research or
did not want to collect stool.

Table 1. Descriptive statistics of enrolled subjects (n = 427).
All
Variables
Severity
Not severe
Severe
Vaccine Type
RotaTeq ®
Rotatirx ®
Mixed dose
None
Unknown
Vaccine Dose
0 doses
1 dose
2 doses
3 doses
Gender
Male
Female
Age:
0-2 months
3-5 months
6-8 months
9-11 months
12-23 months
> 24 months
Race
White
Black
Hispanic
Other
Insurance
Public
Private
None
Unknown

Rotavirus
Positive
(n=119)

Rotavirus
Negative
(n=308)

Sample

p-value

154 (36.1%)
273 (63.9%)

<0.0001

20 (16.8%)
99 (83.2%)

134 (43.5%)
174 (56.5%)

75 (17.6%)
130 (30.4%)
59 (13.8%)
123 (28.8%)
40 (9.4%)

0.0047

15 (12.6%)
23 (19.3%)
8 (6.7%)
65 (55.5%)
8 (6.7%)

60 (19.5%)
107 (34.7%)
51 (16.6%)
58 (18.8%)
32 (10.4%)

123 (28.8%)
44 (10.3%)
172 (40.3%)
88 (20.6%)

0.0090

65 (54.6%)
10 (8.4%)
31 (26.1%)
13 (10.9%)

58 (18.8%)
34 (11.0%)
128 (45.8%)
75 (24.4%)

244 (57.1%)
183 (42.9%)

0.4153

63 (52.9%)
56 (47.1%)

181 (58.8%)
127 (41.2%)

21 (4.9%)
75 (17.6%)
91 (21.3%)
78 (18.3%)
155 (36.3%)
7 (1.6%)

0.2943

5 (4.2%)
12 (10.1%)
19 (16%)
17 (14.3%)
61 (51.3%)
5 (4.2%)

16 (5.2%)
63 (20.5%)
72 (23.4%)
61 (19.8%)
94 (30.5%)
2 (0.6%)

59 (13.8%)
265 (62.1%)
80 (18.7%)
23 (5.4%)

0.0266

16 (13.4%)
81 (68.1%)
14 (11.8%)
8 (6.7%)

43 (14%)
184 (59.7%)
66 (21.4%)
15 (4.9%)

330 (72.2%)
31 (7.3%)
50 (11.7%)
16 (3.7%)

0.0206

86 (72.3%)
11 (9.2%)
16 (13.4%)
6 (5%)

244 (79.2%)
20 (6.5%)
34 (11%)
10 (3.2%)

Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine
dose were defined as those who received at least one dose of RotaTeq® and one dose of
Rotarix®. The vaccine dose category represents the number of rotavirus vaccines a patient had
received at the time of their illness, regardless of the number of doses received. The other race

category included Asian, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or
unknown. Private insurance included PPO and HMO. Public insurance refers to Medicaid
programs.

Table 2. Percentage of vaccine type and dose among subjects with severe disease (n=273).

Vaccine Type
None
RotaTeq ®
Rotarix ®
Mixed
Unknown
Vaccine Doses
0 doses
1 dose
2 doses
3 doses

Severe Disease

p-value

95 (77.2%)
48 (64.0%)
73 (56.5%)
33 (55.9%)
24 (60.0%)

0.005

95 (77.2%)
29 (65.9%)
103 (60.0%)
46 (52.3%)

0.001

Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine
dose were defined as those who received at least one dose of RotaTeq® and one dose of
Rotarix®. The vaccine dose category represents the number of rotavirus vaccines a patient had
received at the time of their illness, regardless of the number of doses received.

Table 3. Univariate analysis of disease severity by covariates.

Variables
Disease Status
Rotavirus Negative
Rotavirus Positive
Vaccine Type
None
RotaTeq ®
Rotarix ®
Mixed
Vaccine Doses
0 doses
1 dose
2 doses
3 doses
Race
White
Black
Hispanic
Other
Insurance
None
Public
Private
Unknown

OR

Severe Disease
95% CI

p-value

1.00
3.8

Referent
2.2-6.4

<0.001

1.00
0.5
0.4
0.4

Referent
0.4-0.9
0.2-0.7
0.2-0.7

0.036
<0.001
0.003

1.00
0.6
0.6
0.4

Referent
0.3-1.3
0.3-0.9
0.2-0.7

0.216
0.024
0.001

1.00
0.4
0.3
0.5

Referent
0.2-0.9
0.1-0.7
0.1-1.4

0.017
0.003
0.176

1.00
0.7
3.1
2.6

Referent
0.4-1.3
1.2-8.3
0.7-9.2

0.0074
0.0856
0.3022

Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine
dose were defined as those who received at least one dose of RotaTeq® and one dose of
Rotarix®. There were 40 (9.4%) patients who received at least one rotavirus vaccine of an
unknown type and were, therefore, not included in the analysis. The vaccine dose category
represents the number of rotavirus vaccines a patient had received at the time of their illness,
regardless of the number of doses received. The other race category included Asian, American
Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or unknown. Private insurance
included PPO and HMO. Public insurance refers to Medicaid programs.

Table 4. Multivariate analysis of disease severity by covariates.

Variables
Vaccine Type
None
RotaTeq ®
Rotarix ®
Mixed
Vaccine Doses
0 doses
1 dose
2 doses
3 doses
Gender
Male
Female
Age
0-2 months
3-5 months
6-8 months
9-11 months
12-23 months
24+ months
Race
White
Black
Hispanic
Other
Insurance
None
Public
Private
Unknown

OR

Severe Disease
95% CI

p-value

1.0
0.1
0.1
0.1

Referent
0.02-0.5
0.01-0.3
0.02-0.5

0.006
0.001
0.004

1.00
0.7
0.7
0.3

Referent
0.3-1.5
0.4-1.1
0.2-0.6

0.400
0.135
<0.001

1.0
0.8

Referent
0.5-1.2

0.354

1.0
1.0
1.4
2.0
1.7
1.7

Referent
0.4-2.8
0.5-3.8
0.7-5.6
0.7-4.5
0.3-12.0

0.937
0.491
0.168
0.254
0.571

1.0
0.4
0.3
0.3

Referent
0.2-0.8
0.1-0.7
0.1-1.1

0.014
0.006
0.063

1.0
1.6
4.0
3.5

Referent
0.9-3.1
1.2-12.9
0.9-14.5

0.128
0.021
0.083

Disease severity was defined using the Vesikari scale. Participants who received a mixed vaccine
dose were defined as those who received at least one dose of RotaTeq® and one dose of
Rotarix®. There were 40 (9.4%) patients who received at least one rotavirus vaccine of an

unknown type and were, therefore, not included in the analysis. The vaccine dose category
represents the number of rotavirus vaccines a patient had received at the time of their illness,
regardless of the number of doses received. The other race category included Asian, American
Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or unknown. Private insurance
included PPO and HMO. Public insurance refers to Medicaid programs.
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